Herein, we tested the potential of this drug delivery system that encapsulates an ATM inhibitor to target and sensitize mammospheres—considered as a model system of BCSCs—to an anticancer drug, while having a comparably lower cytotoxic effect against bulk tumor cells. This evidence concerns the gene ATM and neoplasm.